BHI Sales by Brand
| 12 months to 31st March 2005 | Sales £m |
|
|---|---|---|
| Nurofen | 150 | +8.1% |
| Clearasil | 91 | +6.0% |
| Strepsils | 91 | +9.3% |
| Dermo-cosmetics | 48 | -6.6% |
| Other | 143 | +5.8% |
| Total | 523 | +5.8% |
Sales growth relates to local currency
Notes
Nurofen sales were up 8.1% with particularly strong growth in Australia and New Zealand from expansion of distribution through non-pharmacy retailers and in Russia and central Europe.
Clearasil sales were up 6.0% driven by the Ultra and Mens products and expansion in Italy, Asia and Latin America.
Strepsils sales grew 9.3%. Successful advertising led to growth across Europe and Asia.
Dermo-cosmetics sales were down 6.6% due to lower sales of E45 in the UK and of Lutsine in France.
Other brand sales were up 5.8%.
